30 closest matches · ranked by relevance
Pertussis
Primary: Twenty One Pre-specified Outcomes of Interest as Obtained From International Coding of Diseases (ICD-9) Codes Captured After Adacel Vaccination in Clinical Database — 0…
Epilepsy, Tonic-clonic
Primary: Percentage Participants With Treatment Emergent Adverse Events — 27.3 percentage of participants
Disorder of Soft Tissue
Primary: Assessment of Treatment Site Responses Post Procedure — 78 percentage of participants with any AE
Non Small Cell Lung Cancer · Malignant Pleural Mesothelioma
Primary: Safety Assessment Including Treatment-related Adverse Events (Number of Participants Who Experienced at Least One Adverse Event (AE) or One Serious Adverse Event (SAE))…
Acute Pain · Dysmenorrhea
Primary: Percentage of Patients With an Incidence of Adverse Event (AE) Associated to Potential Liver Damage During the Clinical Evaluation of Patients — 0.0 Percentage of Patients
Parkinson Disease
Primary: Incidence of AE/SAE — 5.16 Percentage of participants
Influenza · Vaccines Adverse Reaction
Primary: Number of Participants Who Had Experienced a New Health Problem or the Worsening of an Existing Health Condition That Resulted in a Medical Consultation — 153 participants
Healthy Volunteers
Primary: Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 4.04 msec
Breast Neoplasms
Primary: Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane — 126; 324; 372; 68 participants
Epilepsy · Monotherapy
Primary: Number of Subjects With at Least One Treatment-emergent Adverse Event (AE) During the Treatment Phase (Maximum of 3.5 Years) — 181; 182 Participants
Patient Safety · Manipulation, Spinal
Primary: Number of Patient Encounters That Report a New or Worsening Symptom — 8 Participants
Sexual Dysfunctions, Psychological
Primary: Frequency of Adverse Events — 331; 206; 58; 51 participants with any adverse event
Acne Vulgaris
Primary: Percent Change From Baseline in Inflammatory, Noninflammatory and Total Lesion Count at Month 12 LOCF — -59.70; -58.80; -58.85 percent change
Essential Hypertension
Primary: Number of Participants Experiencing AEs or ADRs — 184; 59 Participants
Healthy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 3; 4; 4 Participants
Hepatitis C, Chronic
Primary: Incidence of Acute Myocardial Infarction (AMI) — 3.3; 5.2 Events per 1000 person years — p=.68
Hemophilia A
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 15; 59; 2; 7 participants
Chronic Kidney Disease
Primary: Drug-related Adverse Events Consisting of Epoetin Alfa-induced Immunogenicity and Resulting Clinical Effects — 7; 0.18 percentage of participants
Hemorrhoid
Primary: Uneventful Creation of a Functional Staple Line at First Firing of Device — 27 participants
Novel Influenza A/H1N1
Primary: Number of Participants Who Had Experienced a New Health Problem or the Worsening of an Existing Health Condition That Resulted in a Medical Consultation. — 234…
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in 24-Hour Mean Heart Rate Post-dose — -0.19; -1.84; 0.40; -0.09 bpm
Alzheimer's Disease
Primary: Number of Treatment Emergent Adverse Events (TEAEs) in the OLEX — 2130 TEAEs
Atrial Fibrillation
Primary: Incidence Rate of Stroke and Systemic Embolism (SE) — 2.898; 3.563 per patient-year
Chronic Heart Failure With Reduced Ejection Fraction
Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability of LCZ696…
Severe Respiratory Syncytial Virus Infection
Primary: Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection, Serious Arrhythmia and/or Death — 303; 349 participants
Hypercholesterolemia
Primary: Number of Participants With Adverse Events — 327; 728; 342; 718 Participants
Type 1 Diabetes
Primary: Change in A1C From Baseline to End of Study Participation — 0.00; -0.04 Percent
Thrombocythemia, Essential
Primary: Percentage of Participants With At Least One Pre-Defined Event (PDE), Deaths, Pregnancies — 1.0; 0.0; 1.5; 0.7 percentage of participants
Autism
Primary: Adverse Events — 2; 1; 2; 6 participants
Malaria
Primary: Number of Participants With at Least One Adverse Events of Specific Interest (AESI) From Month 0 to Month 79 — 12; 11; 16 Participants